Similarly, a comparison to other second and third generation ALKi that have recently shown benefit with respect to crizotinib in the first line setting (ensartinib in eXalt3, NCT02767804, or lorlatinib in CROWN, NCT03052608) could provide further insights into the mechanisms behind ALK+NSCLC treatment. This evidence concerns the gene ALK and non-small cell lung carcinoma.